Lifeboat Foundation

The discovery of a new type of stem cell in deer antlers could lead to breakthroughs in human regeneration.

NewLimit, a company working towards the radical extension of human healthspan using epigenetic reprogramming has announced it has secured $40 million in Series A funding from prominent investors including Dimension, Founders Fund, and Kleiner Perkins.

This investment further bolsters the company’s belief that therapies to delay, halt or even reverse aging can be found through the exploration of epigenetic reprogramming. With a strong belief that their innovative approach can also address various age-related diseases, NewLimit aims to revolutionize the field of aging biology and pave the way for transformative advancements in healthcare.

Longevity. Technology: Epigenetic reprogramming is an emerging but exciting field of geroscience. It involves the identification of specific sets of transcription factors that can induce changes in gene expression and cellular behavior, effectively reversing or modifying the epigenetic markers associated with aging. This approach offers a unique opportunity to rejuvenate cells and tissues, potentially slowing down or even reversing the effects of aging and its related diseases. NewLimit says that while its products are designed to treat aging itself, the company also believes “these products could treat or prevent many diseases associated with aging, including fibrosis, infectious disease, and neurodegenerative disease.”

A new publication in the May issue of Nature Aging by researchers from Integrated Biosciences, a biotechnology company combining synthetic biology and machine learning to target aging, demonstrates the power of artificial intelligence (AI) to discover novel senolytic compounds, a class of small molecules under intense study for their ability to suppress age-related processes such as fibrosis, inflammation and cancer.

The paper, “Discovering small-molecule senolytics with deep neural networks,” authored in collaboration with researchers from the Massachusetts Institute of Technology (MIT) and the Broad Institute of MIT and Harvard, describes the AI-guided screening of more than 800,000 compounds to reveal three drug candidates with comparable efficacy and superior medicinal chemistry properties than those of senolytics currently under investigation.

“This research result is a significant milestone for both longevity research and the application of artificial intelligence to drug discovery,” said Felix Wong, Ph.D., co-founder of Integrated Biosciences and first author of the publication. “These data demonstrate that we can explore chemical space in silico and emerge with multiple candidate anti-aging compounds that are more likely to succeed in the clinic, compared to even the most promising examples of their kind being studied today.”

Dr. Steven Gazal, an assistant professor of population and public health sciences at the Keck School of Medicine of USC, is on a mission to answer a perplexing question: Why, despite millions of years of evolution, do humans still suffer from diseases?

As part of an international research team, Gazal has made a groundbreaking discovery. They’ve become the first to accurately pinpoint specific base pairs in the human genome that have remained unaltered throughout millions of years of mammalian evolution. These base pairs play a significant role in human disease. Their findings were published in a special Zoonomia edition of the journal Science.

Gazal and his team analyzed the genomes of 240 mammals, including humans, zooming in with unprecedented resolution to compare DNA.

Scientists have reconstructed the oral microbiomes from dozens of ancient humans, revealing previously undiscovered genes.

Scientists reconstructed the oral microbiomes from dozens of ancient humans, revealing extinct genes.

We’re currently working with companies that develop software and tools that make surgery smarter and safer while they empower surgeons and providers to improve patient outcomes, enhance operational efficiency and increase profitability with data-driven surgery using AI, automation and operating room analytics. This is where analytic components such as data lakes and warehouses are already making a difference in healthcare. We’ve seen them capable of powering millions of facts and patient records at a time. Tied to expertise, these tools allow data-informed decisions for measurable improvements in clinical, financial and operational aspects.

For instance, we’ve helped design and develop surgical applications to improve operating room efficiency, tele-surgery, data lake construction and surgical analytics. Clients come back with feedback on our skills and technical experience, feeling supported by the flexibility and technical boost we give their teams.

Collaboration between technology outsourcing companies and healthcare providers can result in considerable optimization, including improved patient care and maximized processes. Tech providers can strive for the perfect collaborative balance with the above key conversations while boosting robust ecosystems, shared platforms and data.

Research published in Nature Communications today, has shown that techniques initially developed for astronomy and ecology can be used to study the microenvironment of solid tumors.

Led by Peter Mac’s 2020 Lea Medal winner Dr. Anna Trigos and Yuzhou Feng, the study looked at patient tumor samples from prostate, colon and breast cancers and identified novel cancer subtypes, new patterns associated with patient survival, and was able to predict which patients were likely to develop metastasis first.

These exciting results have generated significant interest from medical oncologists, pathologists and immunologists.

A recent study published in Nature Neuroscience indicates that, contrary to common belief, the immune cells of the brain, known as microglia, are not all the same. Researchers found that a unique microglial subset with unique features and function is important for establishing proper cognitive functions in mice. Evidence for such microglial subsets exists also for the human brain, opening exciting new possibilities for novel therapies.

An international collaboration led by researchers from University of Helsinki, Karolinska Institutet and University of Seville characterized ARG1⁺ microglia, a subset of microglial cells, that produces the enzyme called arginase-1 (ARG1). Using advanced imaging techniques, the team found that ARG1⁺ microglia are abundant during development and less prevalent in adult animals. Strikingly, these ARG1⁺ microglia are located in specific brain areas important for cognitive functions such as learning, thinking and memory.

“Cognition and memory are crucial components of what makes us human, and microglia are necessary for proper brain development and function. Cognitive decline is a common feature of neurodegenerative and psychiatric conditions like Alzheimer’s and Parkinson’s disease, schizophrenia and depression,” says Dr. Vassilis Stratoulias, senior researcher at the University of Helsinki and lead author of the study.

Immune checkpoint blockade therapies have been revolutionary in the treatment of some cancer types, emerging as one of the most promising treatments for diseases such as melanoma, colon cancer and non-small cell lung cancer.

While in some cases checkpoint blockade therapies elicit a strong immune response that clears tumors, checkpoint inhibitors do not work for all tumor types or all patients. Moreover, some patients who do experience an initial benefit from these therapies see their cancers recur. Only a small minority of patients treated with checkpoint blockade therapies see lasting benefits. Researchers have developed various combination therapy strategies to overcome resistance to checkpoint blockade therapies, with the STING pathway emerging as one of the most attractive lines of inquiry.

In a study published in Advanced Healthcare Materials, a team of MIT researchers engineered a therapeutic cancer vaccine capable of restoring STING signaling and eliminating the majority of tumors in mouse models of colon cancer and melanoma, with minimal side effects. The vaccine also inhibited metastasis in a breast cancer mouse model and prevented the recurrence of tumors in cured mice.